Rare immune disorder study harvests stem cells to unlock t cell mysteries
NCT ID NCT02015013
First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 12 times
Summary
This study aims to collect stem cells from people with a rare condition called idiopathic CD4 lymphocytopenia (ICL) and from healthy volunteers. Participants receive two medications to move stem cells from bone marrow into the blood, where they are collected. The stem cells are then studied in mice to learn how T cells develop and travel in the body. The goal is to better understand ICL, which causes low CD4 T cells and raises infection risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Filgrastim and plerixafor
- What this could lead to
- If successful, this research could reveal why ICL patients have low CD4 T cells, potentially pointing toward new treatments.
- What could go wrong
- This is an early-stage study with only 40 participants, focused on lab research in mice, not on treating humans directly. It may not lead to a therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC CD4-POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States